HopeStage
Back to all studies
CompletedNCT00206141

Quetiapine compared with lithium for bipolar depression

About this title

Seroquel in Bipolar Depression Versus Lithium

Read the official source — NCT00206141
Medication studyAges 18–65Multiple countriesBipolarity
The study in practice

Understand this study

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Kelowna and 75 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateAugust 2005
Recruitment status
Completed
Enrollment listed in the registry
672
Sponsor
AstraZeneca
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Canada, Croatia, Estonia, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT00206141
Official title
Show the full official title

Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Lithium as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbreviated)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Kelowna, Canada · Sydney, Canada · Greater Sudbury, Canada

74 more locations
  • Markham, Canada
  • Mississauga, Canada
  • Orléans, Canada
  • Waterloo, Canada
  • Montreal, Canada
  • Sherbrooke, Canada
  • Osijek, Croatia
  • Split, Croatia
  • Zadar, Croatia
  • Zagreb-Susedgrad, Croatia
  • Kohtla-Järve, Estonia
  • Tallinn, Estonia
  • Tartu, Estonia
  • Berlin, Germany
  • Würzburg, Germany
  • Solo, Indonesia
  • Jakarta, Indonesia
  • Lawang, Indonesia
  • Daugavpils, Latvia
  • Riga, Latvia
  • Kaunas, Lithuania
  • Šiauliai, Lithuania
  • Vilnius, Lithuania
  • Kuala Lumpur, Malaysia
  • Kuching Sarawak, Malaysia
  • Petaling Jaya, Malaysia
  • Brattvåg, Norway
  • Drammen, Norway
  • Fredrikstad, Norway
  • Mysen, Norway
  • Paradis, Norway
  • Davao City, Philippines
  • Iloilo City, Philippines
  • Mandaluyong, Philippines
  • Manila, Philippines
  • Bialystok, Poland
  • Bydgoszcz, Poland
  • Gdynia, Poland
  • Leszno, Poland
  • Lodz, Poland
  • Skorzewo, Poland
  • Wroclaw, Poland
  • Zabrze, Poland
  • Arkhangelsk, Russia
  • Kazan', Russia
  • Lipetsk, Russia
  • Moscow, Russia
  • Nizhny Novgorod, Russia
  • Rostov-on-Don, Russia
  • Saint Petersburg, Russia
  • Saratov, Russia
  • Smolensk, Russia
  • Stavropol, Russia
  • Tver', Russia
  • Yaroslavl, Russia
  • Belgrade, Serbia
  • Čačak, Serbia
  • Kragujevac, Serbia
  • Niš, Serbia
  • Valjevo, Serbia
  • Gyeonggi-do, South Korea
  • Seoul, South Korea
  • Changhua, Taiwan
  • Taipei, Taiwan
  • Dnipropetrovsk, Ukraine
  • Donetsk, Ukraine
  • Kharkiv, Ukraine
  • Kiev, Ukraine
  • Luhansk, Ukraine
  • Lviv, Ukraine
  • Odesa, Ukraine
  • Simferopol, Ukraine
  • Vinnitsa, Ukraine
  • Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is AstraZeneca.

Did this study involve medication?

Yes. The study involved medication, including Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood).

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies